Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 8, 2025

Graphic Packaging Announces Leadership Transition

View original at finance.yahoo.com
Graphic Packaging Announces Leadership Transition Robbert Rietbroek Appointed President and CEO, Effective January 1, 2026 Michael P. Doss to Step Down as President and CEO, Effective December 31, 2025 ATLANTA, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Leading the talented Graphic Packaging team over the past decade has been a privilege and the highlight of my career

    80% confidence
  • We built what we believe is the world's best sustainable consumer packaging innovation platform

    80% confidence
  • Robbert's unique combination of extensive CPG expertise and solid track record of delivering value-creating results positions him well to drive organic growth and world-class execution, and deliver strong and steady free cash flow

    80% confidence
  • The Company reaffirmed its confidence in its 2026 free cash flow targets

    80% confidence
  • Mike has helped transform Graphic Packaging into the industry leader it is today during his 10 years as CEO and 35 years at the Company

    80% confidence
  • Graphic Packaging has the right assets, team and capabilities to execute on Vision 2030 priorities

    80% confidence
  • With the completion of Vision 2025 transformation, we have everything we need to deliver on Vision 2030 goals

    80% confidence
  • The Board is confident that Robbert is the right leader to advance the Company's progress toward achieving Vision 2030 goals

    80% confidence
  • This is the right time for this transition and Robbert is the right person to step into the CEO role to build on the strong foundation and take Graphic Packaging to the next level

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
Graphic Packaging Announces Leadership Transition — Source | Via News | Via News